Thus, its optimal performance and improved safety profile, arising from a natural protection system such as C4BP(β-), supports the development of PRP6-HO7 as a first-in-class biologic for the treatment of SLE and other autoimmune diseases. Here, C4BPB is linked to systemic lupus erythematosus.